DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7
DURECT Corporation (Nasdaq: DRRX) will report its fourth quarter and full year 2021 financial results on March 7, 2022, at 4:30 PM ET. The conference call will provide insights into the company’s financial performance and business developments, including updates on its lead drug candidate, Larsucosterol (DUR-928), which is in clinical trials for treating alcohol-associated hepatitis (AH) and non-alcoholic steatohepatitis (NASH). DURECT holds Fast Track Designation from the FDA for Larsucosterol, reflecting its potential in treating serious liver diseases.
- Larsucosterol (DUR-928) in clinical trials for AH and NASH.
- FDA Fast Track Designation for Larsucosterol indicates potential for expedited review.
- Risks associated with Innocoll's commercialization of POSIMIR.
- Potential delays in clinical trials for Larsucosterol due to COVID-19.
- Uncertainties regarding Fast Track Designation leading to expedited FDA approval.
CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference call after the market close on Monday, March 7, 2022.
Monday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific Time
Toll Free: 877-869-3847
International: 201-689-8261
Conference ID: 13727525
Webcast: https://themediaframe.com/mediaframe/webcast.html?webcastid=qrEvoVo0
About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. Larsucosterol (also known as DUR-928), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for development and commercialization in the United States. Full prescribing information about POSIMIR, including the Boxed Warning, can be found at www.posimir.com. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement. This press release contains forward-looking statements relating to, among other things, DURECT's relationship with Innocoll, statements about the potential for larsucosterol (also known as DUR-928) to treat patients with AH, NASH, multiple acute organ injury, chronic liver diseases and other diseases, ongoing clinical trials of larsucosterol, and the potential benefits of Fast Track Designation. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "may," "expect," "anticipate," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on DURECT's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties that Innocoll may not launch POSIMIR as planned or commercialize POSIMIR successfully, if at all, the risk that the clinical trial of larsucosterol in AH takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that clinical trials of larsucosterol, including AHFIRM, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the lifesaving potential of larsucosterol in a statistically significant manner, the risk that Fast Track Designation for larsucosterol in AH may not lead to faster FDA review or an approval, risks related to DURECT's ability to obtain capital to fund operations and expenses, risks related to market competition, and other risks described in the "Risk Factors" section of DURECT's Quarterly Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission (the "SEC") on November 3, 2021, and in other filings filed from time to time with the SEC. DURECT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER® is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. Larsucosterol (DUR-928) is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.
View original content:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-fourth-quarter-and-full-year-2021-financial-results-and-provide-business-update-on-march-7-301492013.html
SOURCE DURECT Corporation
FAQ
When will DURECT Corporation announce its Q4 and full year 2021 financial results?
What is Larsucosterol and its significance for DURECT Corporation?
What does FDA Fast Track Designation mean for Larsucosterol?
Who will host the conference call for DURECT's financial results?
